Sanofi Adr Stock Today

SNY Stock  USD 57.75  0.06  0.10%   

Performance

Solid

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
Sanofi ADR is trading at 57.75 as of the 16th of March 2025; that is 0.10% increase since the beginning of the trading day. The stock's open price was 57.69. Sanofi ADR has less than a 9 % chance of experiencing financial distress in the next few years and had a solid performance during the last 90 days. Note, on September 6, 2024, Representative John James of US Congress acquired under $15k worth of Sanofi ADR's common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
1st of July 2002
Category
Healthcare
Classification
Health Care
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi-Aventis operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. The company has 2.51 B outstanding shares of which 5.46 M shares are at this time shorted by investors with about 2.38 days to cover. More on Sanofi ADR

Moving against Sanofi Stock

  0.93SRDX SurModicsPairCorr
  0.89MLTX MoonLake ImmunotherapeutiPairCorr
  0.89EMBC Embecta CorpPairCorr
  0.88SMLR Semler ScientificPairCorr
  0.86TELA Tela Bio Earnings Call This WeekPairCorr
  0.83PMVP Pmv PharmaceuticalsPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Sanofi Stock Highlights

ESG Sustainability
Environmental
Governance
Social
PresidentJeanBaptiste Chatillon
Thematic Ideas
Showing 3 out of 4 themes
Old Names[SCRIPPS NTWKS-A - Dusseldorf Stock Exchang, Scripps Networks Interactive Inc]
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, ARCA Pharmaceutical, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Giant Impact, Dividend Beast, Compulsion, Healthcare, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors)
Average Analyst Recommendation
Debt Levels
Sanofi ADR can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sanofi ADR's financial leverage. It provides some insight into what part of Sanofi ADR's total assets is financed by creditors.
Liquidity
Sanofi ADR has 17.91 B in debt with debt to equity (D/E) ratio of 0.3, which may show that the company is not taking advantage of profits from borrowing. Sanofi ADR has a current ratio of 1.27, demonstrating that it may have difficulties to pay its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Sanofi to invest in growth at high rates of return.

Capital Expenditures

1.79 Billion
Sanofi ADR (SNY) is traded on NASDAQ Exchange in USA. It is located in 46, avenue de la Grande Armée, Paris, France, 75017 and employs 82,878 people. Sanofi ADR is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 145.02 B. Sanofi ADR runs under Pharmaceuticals sector within Health Care industry. The entity has 2.51 B outstanding shares of which 5.46 M shares are at this time shorted by investors with about 2.38 days to cover. Sanofi ADR has about 6.9 B in cash with 9.08 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76.
Check Sanofi ADR Probability Of Bankruptcy
Ownership Allocation
Sanofi ADR shows a total of 2.51 Billion outstanding shares. About 89.41 % of Sanofi ADR outstanding shares are held by general public with 10.59 % by institutional holders. Please note that on September 6, 2024, Representative John James of US Congress acquired under $15k worth of Sanofi ADR's common stock.
Check Sanofi Ownership Details

Sanofi Stock Institutional Holders

InstituionRecorded OnShares
Franklin Resources Inc2024-12-31
3.8 M
Nuveen Asset Management, Llc2024-12-31
3.7 M
Mondrian Investment Partners Ltd2024-12-31
3.5 M
Magnetar Financial Llc2024-12-31
3.3 M
Envestnet Asset Management Inc2024-12-31
3.1 M
Natixis Advisors, Llc.2024-12-31
2.9 M
Goldman Sachs Group Inc2024-12-31
2.9 M
Raymond James & Associates2024-09-30
2.8 M
Bank Of New York Mellon Corp2024-12-31
2.8 M
Dodge & Cox2024-12-31
75.2 M
Fisher Asset Management, Llc2024-12-31
12.5 M
View Sanofi ADR Diagnostics

Sanofi ADR Historical Income Statement

At this time, Sanofi ADR's EBIT is fairly stable compared to the past year. EBITDA is likely to rise to about 11.3 B in 2025, whereas Depreciation And Amortization is likely to drop slightly above 3.3 B in 2025. View More Fundamentals

Sanofi Stock Against Markets

Sanofi ADR Corporate Management

Roy PapatheodorouExecutive CounselProfile
FranoisXavier RogerChief OfficerProfile
Paul HudsonCEO DirectorProfile
Madeleine RoachExecutive OperationsProfile
Pierre ChancelSenior MarketingProfile
Bruno MnardChief officerProfile
Dante BeccariaGlobal VPProfile

Additional Tools for Sanofi Stock Analysis

When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.